Sparsentan Patent Expiration
Sparsentan is Used for slowing the progression of primary immunoglobulin A nephropathy (IgAN) in adults at risk of rapid disease progression. It was first introduced by Travere Therapeutics Inc
Sparsentan Patents
Given below is the list of patents protecting Sparsentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Filspari | US9662312 | Method For Treating Glomerulosclerosis | Mar 29, 2030 | Travere |
| Filspari | US9993461 | Method for treating disorders associated with glomerular function | Mar 29, 2030 | Travere |
Sparsentan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sparsentan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria | Brigham and Women's Hospital | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy | University of Leicester | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | Travere Therapeutics, Inc. | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |